"For many decades, federal policy has sought to strike the right balance...

... between maintaining the incentives needed to promote for innovation and the development of new drugs, and keeping medicines affordable. That balance...never anticipated companies acquiring off-patent drugs and then jacking up their prices to enormous heights and doing so, as one executive essentially put it, 'because I can,' but that is exactly what we have seen in recent months."

— Sen. Susan Collins (R-Maine), who chairs the Senate Special Committee on Aging, said at a Dec. 9 hearing of the committee.